Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $72.67

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $75.00.

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. William Blair began coverage on shares of Enliven Therapeutics in a research note on Tuesday. They set an “outperform” rating for the company. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, The Goldman Sachs Group raised their target price on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th.

Enliven Therapeutics Stock Performance

ELVN opened at $59.82 on Friday. The company has a market capitalization of $4.38 billion, a PE ratio of -35.82 and a beta of 0.27. The stock’s fifty day moving average is $52.99 and its 200-day moving average is $41.97. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts forecast that Enliven Therapeutics will post -1.69 EPS for the current fiscal year.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the sale, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This trade represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 196,849 shares of company stock worth $11,344,257. Insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Enliven Therapeutics by 18.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,072 shares of the company’s stock valued at $4,064,000 after buying an additional 12,597 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Enliven Therapeutics in the second quarter worth approximately $537,000. Seven Fleet Capital Management LP purchased a new position in shares of Enliven Therapeutics in the second quarter worth approximately $18,543,340,000. Artia Global Partners LP acquired a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $3,659,000. Finally, Bamco Inc. NY acquired a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $381,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.